Plasma fluorescein and fluorescein glucuronide in patients with selected eye diseases

  • Norman P. Blair
  • Michael A. Evans
  • Timothy S. Lesar
  • Michael Willett
Clinical Investigations


Systemically administered fluorescein (F) is rapidly transformed to the fluorescent metabolite fluorescein glucuronide (FG). Little is known about how diseases can influence the synthesis or disposition of FG. We studied F and FG in the plasma ultrafiltrate of 75 people who were normal or had diabetes, retinitis pigmentosa, or idiopathic rhegmatogenous retinal detachment. F and FG were determined by high-performance liquid chromatography. The concentration of FG was comparable to F 1 h after an intravenous injection of F, both in normal subjects and in patients with retinitis pigmentosa, which suggests that FG may not be an important contributor to the vitreous fluorescence at that time. At later times FG substantially exceeded F. The concentration of FG was significantly higher in diabetics than in the other groups 14 h after an oral dose of F. Accordingly, the possible effect of disease on plasma dye concentrations should be considered in studies measuring F by fluorescence hours after systemic F administration, since this could influence the intraocular fluorescence irrespective of any alteration in ocular function.


Public Health Chromatography Liquid Chromatography Fluorescein Oral Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Araie M, Sawa M, Nagataki S, Mishima S (1980) Aqueous humor dynamics in man as studied by oral fluorescein. Jpn J Ophthalmol 24:346–362Google Scholar
  2. 2.
    Blair NP, Zeimer RC, Rusin MM, Cunha-Vaz JG (1983) Outward transport of fluorescein from the vitreous in normal human subjects. Arch Ophthalmol 101:1117–1121Google Scholar
  3. 3.
    Blair NP, Evans MA, Lesar TS, Zeimer RC (1986) Fluorescein and fluorescein glucuronide pharmacokinetics after intravenous injection. Invest Ophthalmol Vis Sci 27:1107–1114Google Scholar
  4. 4.
    Chahal PS, Neal MJ, Kohner EM (1985) Metabolism of fluorescein after intravenous administration. Invest Ophthalmol Vis Sci 26:764–768Google Scholar
  5. 5.
    Chen SC, Nakamura H, Tamura Z (1980) Studies on the metabolites of fluorescein in rabbit and human urine. Chem Pharm Bull 28:1403–1407Google Scholar
  6. 6.
    Chen SC, Nakamura H, Tamura Z (1980) Determination of fluorescein and fluorescein monoglucuronide excreted in urine. Chem Pharm Bull (Tokyo) 28:2812–2816Google Scholar
  7. 7.
    Cunha-Vaz J, Faria de Abreu JR, Campos AJ, Figo GM (1975) Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol 59:649–656Google Scholar
  8. 8.
    Goldmann H (1950) Ueber Fluorescein in der menschlichen Vorderkammer: Das Kammerwasser-Minutenvolumen des Menschen. Ophthalmologica 119:65–95Google Scholar
  9. 9.
    Grotte D, Mattox V, Brubaker RF (1983) Fluorescein glucuronide: Can this metabolite interfere with fluorescein tracer studies? Trans Am Ophthalmol Soc 81:125–129Google Scholar
  10. 10.
    Grotte D, Mattox V, Brubaker R (1985) Fluorescent, physiological and pharmacological properties of fluorescein glucuronide. Exp Eye Res 40:23–33Google Scholar
  11. 11.
    Kitano S, Hori S, Nagataki S (1988) Transport of fluorescein in the rabbit eye after treatment with sodium iodate. Exp Eye Res 46:863–870Google Scholar
  12. 12.
    Lund-Andersen H, Larsen M, Dalgaard P, Olsen W (1987) Fluorescein and fluorescein glucuronide in the vitreous body of diabetic patients. Graefe's Arch Clin Exp Ophthalmol 225:173–176Google Scholar
  13. 13.
    McLaren JW, Brubaker RF (1986) Measurement of fluorescein and fluorescein monoglucuronide in the living human eye. Invest Ophthalmol Vis Sci 27:966–974Google Scholar
  14. 14.
    Mallick KS, Zeimer RC, Fishman GA, Blair NP, Anderson RJ (1984) Transport of fluorescein in the ocular posterior segment in retinitis pigmentosa. Arch Ophthalmol 102:691–696Google Scholar
  15. 15.
    Nagataki S (1975) Aqueous humor dynamics of human eyes as studied using fluorescein. Jpn J Ophthalmol 19:235–249Google Scholar
  16. 16.
    Neault TR, McLaren JW, Brubaker JH, Brubaker RF (1986) Spectral shift of fluorescein and carboxyfluorescein in the anterior chamber of the rabbit eye following systemic administration. Curr Eye Res 5:337–341Google Scholar
  17. 17.
    Palestine AG, Brubaker RF (1981) Pharmacokinetics of fluorescein in the vitreous. Invest Ophthalmol Vis Sci 21:542–549Google Scholar
  18. 18.
    Plehwe WE, Chahal PS, Fallon TJ, Cunningham JR, Neal MJ, Kohner EM (1987) Role of fluorescein glucuronide and its metabolism in vitreous fluorophotometry. Exp Eye Res 44:209–215Google Scholar
  19. 19.
    Sakai Y, Seto C, Araie M (1986) Study of fluorescein glucuronide. 1 Isolation from urine. Graefe's Arch Clin Exp Ophthalmol 224:110–112Google Scholar
  20. 20.
    Selan F, Blair NP, Evans MA (1985) High-performance liquid chromatographic analysis for fluorescein and fluorescein monoglucuronide in plasma. J Chromatogr 338:213–218Google Scholar
  21. 21.
    Seto C, Araie M, Takase M, Minoda K (1984) The effects of fluorescein monoglucuronide on the calculation of the transfer coefficient by diffusion (kdpa) after systemic administration of fluorescein. Nippon Ganka Gakkai Zasshi 88:1572–1580Google Scholar
  22. 22.
    Seto C, Araie M, Takase M (1986) Study of fluorescein glucuronide. II. A comparative ocular kinetic study of fluorescein and fluorescein glucuronide. Graefe's Arch Clin Exp Ophthalmol 224:113–117Google Scholar
  23. 23.
    Waltman SR, Oestrich C, Krupin T, Hanish S, Ratzan S, Santiago J, Kilo C (1978) Quantitative vitreous fluorophotometry. A sensitive technique for measuring early breakdown of the blood-retinal barrier in young diabetic patients. Diabetes 27:85–87Google Scholar
  24. 24.
    Zeimer RC, Blair NP, Cunha-Vaz JG (1983) Pharmacokinetic interpretation of vitreous fluorophotometry. Invest Ophthalmol Vis Sci 24:1374–1381Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Norman P. Blair
    • 1
  • Michael A. Evans
    • 2
  • Timothy S. Lesar
    • 3
    • 4
  • Michael Willett
    • 3
    • 5
  1. 1.Department of OphthalmologyUniversity of Illinois at ChicagoChicagoUSA
  2. 2.Department of PharmacologyCollege of Medicine, University of Illinois at ChicagoChicagoUSA
  3. 3.College of Pharmacy, University of Illinois at ChicagoChicagoUSA
  4. 4.Albany Medical Center HospitalAlbanyUSA
  5. 5.Truman Medical CenterKansas CityUSA

Personalised recommendations